Clinical Study of Mesenchymal Stem Cell Treatment for Acute Respiratory Distress Syndrome Induced by Epidemic Influenza A (H7N9) Infection: A Hint for COVID-19 Treatment

Jiajia Chen, Chenxia Hu, Lijun Chen, Lingling Tang, Yixin Zhu, Xiaowei Xu, Lu Chen, Hainv Gao, Xiaoqing Lu, Liang Yu, Xiahong Dai, Charlie Xiang, Lanjuan Li, Jiajia Chen, Chenxia Hu, Lijun Chen, Lingling Tang, Yixin Zhu, Xiaowei Xu, Lu Chen, Hainv Gao, Xiaoqing Lu, Liang Yu, Xiahong Dai, Charlie Xiang, Lanjuan Li

Abstract

H7N9 viruses quickly spread between mammalian hosts and carry the risk of human-to-human transmission, as shown by the 2013 outbreak. Acute respiratory distress syndrome (ARDS), lung failure, and acute pneumonia are major lung diseases in H7N9 patients. Transplantation of mesenchymal stem cells (MSCs) is a promising choice for treating virus-induced pneumonia, and was used to treat H7N9-induced ARDS in 2013. The transplant of MSCs into patients with H7N9-induced ARDS was conducted at a single center through an open-label clinical trial. Based on the principles of voluntariness and informed consent, 44 patients with H7N9-induced ARDS were included as a control group, while 17 patients with H7N9-induced ARDS acted as an experimental group with allogeneic menstrual-blood-derived MSCs. It was notable that MSC transplantation significantly lowered the mortality of the experimental group, compared with the control group (17.6% died in the experimental group while 54.5% died in the control group). Furthermore, MSC transplantation did not result in harmful effects in the bodies of four of the patients who were part of the five-year follow-up period. Collectively, these results suggest that MSCs significantly improve the survival rate of H7N9-induced ARDS and provide a theoretical basis for the treatment of H7N9-induced ARDS in both preclinical research and clinical studies. Because H7N9 and the coronavirus disease 2019 (COVID-19) share similar complications (e.g., ARDS and lung failure) and corresponding multi-organ dysfunction, MSC-based therapy could be a possible alternative for treating COVID-19.

Keywords: Acute respiratory distress syndrome; COVID-19; Epidemic Influenza A; H7N9; Mesenchymal stem cell; Stem cell therapeutics.

© 2020 THE AUTHORS.

Figures

Fig. 1
Fig. 1
The CONSORT diagram for the clinical trial of H7N9-infected patients. Forty-four patients with H7N9-induced ARDS were included as a control group and 17 patients with H7N9-induced ARDS acted as an experimental group with allogeneic, menstrual-blood-derived MSCs. MSC transplantation significantly lowered the mortality compared with the control group. Follow-up laboratory tests were taken for four H7N9-induced ARDS patients in the experimental group over five years.
Fig. 2
Fig. 2
Follow-up of four patients for five years after MSC treatment; images from one of these four patients are provided here. (a) Before MSC transplantation, some fibrillations were present. Radiologic changes included linear fibrosis, air bronchogram, bronchiectasia, isolated areas of pleural thickening, ground-glass opacities, and hydrothorax after MSC transplantation for (b) 1 week, (c) 24 weeks, (d) 1 year, and (e) 5 years. After MSC transplantation for 24 weeks and one year, all patients showed improvement on CCT.

References

    1. Rambaut A., Pybus O.G., Nelson M.I., Viboud C., Taubenberger J.K., Holmes E.C. The genomic and epidemiological dynamics of human influenza A virus. Nature. 2008;453:615–619.
    1. Uyeki T.M., Katz J.M., Jernigan D.B. Novel influenza A viruses and pandemic threats. Lancet. 2017;389(10085):2172–2174.
    1. Swayne D.E., Suarez D.L. Highly pathogenic avian influenza. Rev Sci Technol. 2000;19:463–482.
    1. Gao R., Cao B., Hu Y., Feng Z., Wang D., Hu W. Human infection with a novel avian-origin influenza A (H7N9) virus. N Engl J Med. 2013;368:1888–1897.
    1. Liu D., Shi W., Shi Y., Wang D., Xiao H., Li W. Origin and diversity of novel avian influenza A H7N9 viruses causing human infection: phylogenetic, structural, and coalescent analyses. Lancet. 2013;381:1926–1932.
    1. Chen Y., Liang W., Yang S., Wu N., Gao H., Sheng J. Human infections with the emerging avian influenza A H7N9 virus from wet market poultry: clinical analysis and characterisation of viral genome. Lancet. 2013;381(9881):1916–1925.
    1. Li Y.H., Hu C.Y., Wu N.P., Yao H.P., Li L.J. Molecular characteristics, functions, and related pathogenicity of MERS-CoV proteins. Engineering. 2019;5:940–947.
    1. Pantin-Jackwood M.J., Miller P.J., Spackman E., Swayne D.E., Susta L., Costa-Hurtado M. Role of poultry in the spread of novel H7N9 influenza virus in China. J Virol. 2014;88(10):5381–5390.
    1. Lee S.S., Wong N.S., Leung C.C. Exposure to avian influenza H7N9 in farms and wet markets. Lancet. 2013;381(9980):1815.
    1. Xu L., Bao L., Deng W., Dong L., Zhu H., Chen T. Novel avian-origin human influenza A (H7N9) can be transmitted between ferrets via respiratory droplets. J Infect Dis. 2014;209(4):551–556.
    1. Jonges M., Welkers M.R., Jeeninga R.E., Meijer A., Schneeberger P., Fouchier R.A. Emergence of the virulence-associated PB2 E627K substitution in a fatal human case of highly pathogenic avian influenza virus A (H7N7) infection as determined by Illumina ultra-deep sequencing. J Virol. 2014;88:1694–1702.
    1. Yu L., Wang Z., Chen Y., Ding W., Jia H., Chan J.F.W. Clinical, virological, and histopathological manifestations of fatal human infections by avian influenza A (H7N9) virus. Clin Infect Dis. 2013;57(10):1449–1457.
    1. Robertson I.D. Disease control, prevention and on-farm biosecurity: the role of veterinary epidemiology. Engineering. 2020;6(1):20–25.
    1. Li Q., Zhou L., Zhou M., Chen Z., Li F., Wu H. Epidemiology of human infections with avian influenza A (H7N9) virus in China. N Engl J Med. 2014;370:520–532.
    1. Wang C., Yu H., Horby P.W., Cao B., Wu P., Yang S. Comparison of patients hospitalized with influenza A subtypes H7N9, H5N1, and 2009 pandemic H1N1. Clin Infect Dis. 2014;58:1095–1103.
    1. Zhou L., Ren R., Yang L., Bao C., Wu J., Wang D. Sudden increase in human infection with avian influenza A (H7N9) virus in China, September–December 2016. Western Pac Surveill Response J. 2017;8:6–14.
    1. Wang X., Jiang H., Wu P., Uyeki T.M., Feng L., Lai S. Epidemiology of avian influenza A H7N9 virus in human beings across five epidemics in mainland China, 2013–17: an epidemiological study of laboratory-confirmed case series. Lancet Infect Dis. 2017;17:822–832.
    1. Zhou J., Wang D., Gao R., Zhao B., Song J., Qi X. Biological features of novel avian influenza A (H7N9) virus. Nature. 2013;499(7459):500–503.
    1. Wang B., Yao M., Lv L., Ling Z., Li L. The human microbiota in health and disease. Engineering. 2017;3(1):71–82.
    1. Sivanandy P., Foong Z.X., Lee W.K., Wei Y.T., Kuan H.E., Lian C.L. A review on current trends in the treatment of human infection with H7N9-avian influenza A. J Infect Public Health. 2018;12(2):153–158.
    1. Hui D.S., Lee N., Chan P.K., Beigel J.H. The role of adjuvant immunomodulatory agents for treatment of severe influenza. Antivir Res. 2018;150:202–216.
    1. Yang M., Gao H., Chen J., Xu X., Tang L., Yang Y. Bacterial coinfection is associated with severity of avian influenza A (H7N9), and procalcitonin is a useful marker for early diagnosis. Diagn Microbiol Infect Dis. 2016;84:165–169.
    1. Zhu N., Zhang D., Wang W., Li X., Yang B., Song J. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382:727–733.
    1. Huang C., Wang Y., Li X., Ren L., Zhao J., Hu Y. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506.
    1. Sahin A.R., Erdogan A., Agaoglu P.M., Dineri Y., Cakirci A.Y., Senel M.E. 2019 novel coronavirus (COVID-19) outbreak: a review of the current literature. EJMO. 2020;4(1):1–7.
    1. Li T., Lu H., Zhang W. Clinical observation and management of COVID-19 patients. Emerg Microbes Infect. 2020;9(1):687–690.
    1. Chan J.F.W., Yuan S., Kok K.H., To K.K.W., Chu H., Yang J. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. 2020;395(10223):514–523.
    1. Chen H., Guo J., Wang C., Luo F., Yu X., Zhang W. Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records. Lancet. 2020;395(10226):809–815.
    1. Xu X., Wu X., Jiang X., Xu K., Ying L., Ma C. Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-CoV-2) outside of Wuhan, China: retrospective case series. BMJ. 2020;368
    1. Xu Z., Shi L., Wang Y., Zhang J., Huang L., Zhang C. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020;8(4):420–422.
    1. Wilson J.G., Liu K.D., Zhuo H., Caballero L., McMillan M., Fang X. Mesenchymal stem (stromal) cells for treatment of ARDS: a phase 1 clinical trial. Lancet Respir Med. 2015;3:24–32.
    1. Khoury M., Alcayaga-Miranda F., Illanes S.E., Figueroa F.E. The promising potential of menstrual stem cells for antenatal diagnosis and cell therapy. Front Immunol. 2014;5:205.
    1. Chen L., Qu J., Cheng T., Chen X., Xiang C. Menstrual blood-derived stem cells: toward therapeutic mechanisms, novel strategies, and future perspectives in the treatment of diseases. Stem Cell Res Ther. 2019;10:406.
    1. Chen L., Qu J., Xiang C. The multi-functional roles of menstrual blood-derived stem cells in regenerative medicine. Stem Cell Res Ther. 2019;10(1):1–10.
    1. Wang Q., Zhang Z., Shi Y., Jiang Y. Emerging H7N9 influenza A (novel reassortant avian-origin) pneumonia: radiologic findings. Radiology. 2013;268:882–889.
    1. Gao H.N., Lu H.Z., Cao B., Du B., Shang H., Gan J.H. Clinical findings in 111 cases of influenza A (H7N9) virus infection. N Engl J Med. 2013;368(24):2277–2285.
    1. Wu X., Luo Y., Chen J., Pan R., Xiang B., Du X. Transplantation of human menstrual blood progenitor cells improves hyperglycemia by promoting endogenous progenitor differentiation in type 1 diabetic mice. Stem Cells Dev. 2014;23(11):1245–1257.
    1. Chen L., Zhang C., Chen L., Wang X., Xiang B., Wu X. Human menstrual blood-derived stem cells ameliorate liver fibrosis in mice by targeting hepatic stellate cells via paracrine mediators. Stem Cells Transl Med. 2017;6:272–284.
    1. Zheng G., Huang L., Tong H., Shu Q., Hu Y., Ge M. Treatment of acute respiratory distress syndrome with allogeneic adipose-derived mesenchymal stem cells: a randomized, placebo-controlled pilot study. Respir Res. 2014;15:39.
    1. McHugh L.G., Milberg J.A., Whitcomb M.E., Schoene R.B., Maunder R.J., Hudson L.D. Recovery of function in survivors of the acute respiratory distress syndrome. Am J Respir Crit Care. 1994;150(1):90–94.
    1. Herridge M.S., Cheung A.M., Tansey C.M., Matte-Martyn A., Diaz-Granados N., Al-Saidi F. One-year outcomes in survivors of the acute respiratory distress syndrome. N Engl J Med. 2003;348(8):683–693.
    1. Luyt C.E., Combes A., Becquemin M.H., Beigelman-Aubry C., Hatem S., Brun A.L. Long-term outcomes of pandemic 2009 influenza A (H1N1)-associated severe ARDS. Chest. 2012;142:583–592.
    1. Lu P.X., Wang Y.X., Zhou B.P., Ge Y., Zhu W.K., Chen X.C. Radiological features of lung changes caused by avian influenza subtype A H5N1 virus: report of two severe adult cases with regular follow-up. CMJ. 2010;123(1):100–104.
    1. Bai L., Gu L., Cao B., Zhai X.L., Lu M., Lu Y. Clinical features of pneumonia caused by 2009 influenza A (H1N1) virus in Beijing, China. Chest. 2011;139(5):1156–1164.
    1. Dowdy D.W., Eid M.P., Dennison C.R., Mendez-Tellez P.A., Herridge M.S., Guallar E. Quality of life after acute respiratory distress syndrome: a meta-analysis. Intens Care Med. 2006;32:1115–1124.
    1. Cohen J., Normile D. New SARS-like virus in China triggers alarm. Science. 2020;367(6475):234–235.
    1. Lu R., Zhao X., Li J., Niu P., Yang B., Wu H. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;359:565–574.
    1. Li Q., Guan X., Wu P., Wang X., Zhou L., Tong Y. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med. 2020;382:1199–1207.
    1. Zhou M., Zhang X., Qu J. Coronavirus disease 2019 (COVID-19): a clinical update. Front Med. 2020;14(2):126–135.
    1. Chang D., Lin M., Wei L., Xie L., Zhu G., Dela Cruz C.S. Epidemiologic and clinical characteristics of novel coronavirus infections involving 13 patients outside Wuhan China. JAMA. 2020;323(11):1092–1093. In press.
    1. Volarevic V., Markovic B.S., Gazdic M., Volarevic A., Jovicic N., Arsenijevic N. Ethical and safety issues of stem cell-based therapy. Int J Med Sci. 2018;15(1):36–45.
    1. Gao F., Chiu S.M., Motan D.A., Zhang Z., Chen L., Ji H.L. Mesenchymal stem cells and immunomodulation: current status and future prospects. Cell Death Dis. 2016;7
    1. Shi M., Liu Z., Wang Y., Xu R., Sun Y., Zhang M. A pilot study of mesenchymal stem cell therapy for acute liver allograft rejection. Stem Cells Transl Med. 2017;6(12):2053–2061.
    1. Xiang B., Chen L., Wang X., Zhao Y., Wang Y., Xiang C. Transplantation of menstrual blood-derived mesenchymal stem cells promotes the repair of LPS-induced acute lung injury. Int J Mol Sci. 2017;18(4):E689.
    1. Hu C., Li L. Preconditioning influences mesenchymal stem cell properties in vitro and in vivo. J Cell Mol Med. 2018;22(3):1428–1442.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다